Hosted on MSN12h
Four regimens fail endpoints simultaneously in HEALEY ALS trialALS candidates from Biohaven, Prilenia, Clene and UCB have all failed to halt disease progression versus placebo in the US-wide platform trial.
Kiromic BioPharma (KRBP) reported continued efficacy results from the 10-month follow-up visit for the fourth patient enrolled in its ...
Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s (AZN) IMFINZI, ...
AstraZeneca (AZN) has reported positive results from an analysis of its NIAGARA Phase 3 study of Imfinzi in the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback